Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients. 2004

Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. sis@dadlnet.dk

High blood levels of the soluble urokinase receptor (suPAR) strongly predict increased mortality in human immunodeficiency virus-1 (HIV-1)-infected patients. This study investigated the plasma concentration of suPAR in 29 treatment-naive HIV-1-infected patients during 5 years treatment with highly active antiretroviral therapy (HAART). Plasma suPAR decreased after introducing HAART, most pronounced during the first treatment year. The change in plasma suPAR was independent of changes in viral replication and CD4+ cells but it was strongly correlated with plasma levels of the soluble TNF receptor II. Compared with healthy individuals, plasma suPAR and sTN-FrII was increased in untreated patients. After initiating HAART, plasma sTNFrII remained increased whereas plasma suPAR decreased to a level comparable with healthy individuals. The present data indicate that the circulating suPAR level is linked to inflammation in untreated as well as HAART-treated HIV-1-infected patients.

UI MeSH Term Description Entries
D008297 Male Males
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D047889 Receptors, Tumor Necrosis Factor, Type II A tumor necrosis factor receptor subtype that is expressed primarily in IMMUNE SYSTEM cells. It has specificity for membrane-bound form of TUMOR NECROSIS FACTORS and mediates intracellular-signaling through TNF RECEPTOR ASSOCIATED FACTORS. Antigens, CD120b,CD120b Antigens,Receptors, Tumor Necrosis Factor, Member 1B,Tumor Necrosis Factor Receptor Superfamily, Member 1B,Tumor Necrosis Factor Receptor Type II,CD 120b Antigen,CD120b Antigen,TNF-R2,TNF-R75,TNF-RII,TNF-sR75,TNFR p75,TNFR p80,TNFR2,TNFRSF1B Receptor,Tumor Necrosis Factor Receptor 2,Tumor Necrosis Factor Receptor 75,Tumor Necrosis Factor Receptor Type 2,120b Antigen, CD,Antigen, CD 120b,Antigen, CD120b,Receptor, TNFRSF1B

Related Publications

Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
September 2000, AIDS research and human retroviruses,
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
February 2008, Journal of medical virology,
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
August 2011, Journal of acquired immune deficiency syndromes (1999),
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
August 2010, Journal of acquired immune deficiency syndromes (1999),
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
August 2011, HIV medicine,
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
July 2008, HIV medicine,
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
June 2000, Clinical immunology (Orlando, Fla.),
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
February 2002, The Lancet. Infectious diseases,
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
May 2010, Microcirculation (New York, N.Y. : 1994),
Sisse R Ostrowski, and Terese L Katzenstein, and Timo Piironen, and Jan Gerstoft, and Bente K Pedersen, and Henrik Ullum
January 2002, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!